Find News

Filter articles

Showing 3261 to 3270 of 3709 results

CJEU lays down stem cell patent rules

EU18-12-2014Legal developments

Europe’s highest court has said that an organism incapable of developing into a human does not constitute a human embryo and therefore uses of it can be patented.

Latest US patent guidelines could ‘muddy the waters’

US17-12-2014Legal developments

The US Patent and Trademark Office has issued new guidance for determining what claims are eligible for patenting, with one lawyer saying it could “muddy the waters”.

Bayer’s Nexavar appeal rejected by Indian Supreme Court

India16-12-2014Legal developments

Bayer has lost an attempt to block a generic version of its cancer drug Nexavar (Sorafenib) in India after the country’s highest court rejected an appeal from the German pharmaceutical company.

Drug makers on brink of $65bn patent cliff, says report


Pharmaceutical companies will suffer an estimated $65 billion drop in sales over the next five years due to the expiry of patents protecting several leading drugs, according to a UK research and consulting firm.

Acne drug at centre of ‘first’ IPR ruling of its kind


Pharmaceutical company Supernus and its subsidiary Galderma have had their Oracea (doxycycline) acne treatment drug protected from a generic challenge, in a decision dubbed the “first of its kind”.

Partner joins King & Spalding


Law firm King & Spalding has appointed a partner to its office in Washington, DC.

Merck insists on buyout despite generic blow


Pharmaceutical company Merck has said it will press on with an $8.4 billion buyout of Cubist Pharmaceuticals despite a court ruling that could pave the way for a generic version of a lucrative Cubist drug.

Sandoz too quick off the mark in Amgen suit: US court


Novartis’s generic arm Sandoz has failed to win a patent case regarding its biosimilar version of Amgen’s psoriasis and arthritis drug Enbrel (etanercept).

AstraZeneca and Ranbaxy win ‘pay-for-delay’ case

India, US08-12-2014Legal developments

A US court has spared drug companies AstraZeneca and Ranbaxy Laboratories a potentially hefty fine after ruling that a ‘pay-for-delay’ deal between them did not violate antitrust grounds.

MIT and Harvard sign genome licensing deal

US05-12-2014Mergers & acquisitions

US research centre the Broad Institute of Massachusetts Institute of Technology and Harvard has entered into a worldwide licensing deal with Editas Medicines, granting it access to IP covering genome technology and human therapeutic applications.

Showing 3261 to 3270 of 3709 results